Login to Your Account



Clinic roundup


Thursday, March 13, 2014

Senesco Technologies Inc., of Bridgewater, N.J., opened two sites in the Republic of South Africa in its open-label, multiple-dose, dose-escalation phase Ib/IIa study of SNS01-T, which is evaluating the safety and tolerability in 15 patients with relapsed or refractory multiple myeloma or mantle cell or diffuse large B-cell lymphoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription